Publications
Detailed Information
First-line Pembrolizumab Versus Pembrolizumab Plus Chemotherapy Versus Chemotherapy Alone in Non-small-cell Lung Cancer: A Systematic Review and Network Meta-analysis
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Ryul | - |
dc.contributor.author | Keam, Bhumsuk | - |
dc.contributor.author | Hahn, Seokyung | - |
dc.contributor.author | Ock, Chan-Young | - |
dc.contributor.author | Kim, Miso | - |
dc.contributor.author | Kim, Tae Min | - |
dc.contributor.author | Kim, Dong-Wan | - |
dc.contributor.author | Heo, Dae Seog | - |
dc.date.accessioned | 2020-04-27T10:56:18Z | - |
dc.date.available | 2020-04-27T10:56:18Z | - |
dc.date.created | 2020-03-25 | - |
dc.date.issued | 2019-09 | - |
dc.identifier.citation | Clinical Lung Cancer, Vol.20 No.5, pp.331-338.e4 | - |
dc.identifier.issn | 1525-7304 | - |
dc.identifier.other | 93346 | - |
dc.identifier.uri | https://hdl.handle.net/10371/165201 | - |
dc.description.abstract | Immunotherapy has revolutionized lung cancer management. Our study focused on the efficacy of first-line pembrolizumab for treatment of non-small-cell lung cancer by summarizing 4 phase III clinical trials. This analysis revealed that pembrolizumab in combination with chemotherapy exhibited better survival outcome than pembrolizumab monotherapy. Background: This study aimed to comprehensively review the available evidence regarding the efficacy of first-line pembrolizumab for advanced/metastatic non-small-cell lung cancer (NSCLC), and to compare pembrolizumab monotherapy versus pembrolizumab plus chemotherapy versus chemotherapy alone. Materials and Methods: A search of the PubMed, EMBASE, and Cochrane Library databases was performed in July 2018, and abstracts from the American Society of Clinical Oncology meetings (2015-2018) were reviewed. Summaries of the results were pooled using a random-effect model to determine the pooled hazard ratio (HR) for progression-free survival (PFS), overall survival (OS), and their 95% confidence intervals (Cis). A network meta-analysis was used to indirectly compare pembrolizumab monotherapy with pembrolizumab plus chemotherapy. Results: A total of 4 relevant phase III trials comprising 2754 patients were identified. Pembrolizumab (with or without chemotherapy) led to significant improvements in OS and PFS, irrespective of the programmed cell death ligand 1 (PD-L1) tumor proportion score (TPS). In particular, for the subgroup with PD-L1 TPS > 50%, the HR of PFS was 0.49 (95% CI, 0.32-0.76; P = .001), and that of OS was 0.57 (95% CI, 0.45-0.73; P < .001). In terms of PFS, pembrolizumab plus chemotherapy was superior to pembrolizumab monotherapy with an HR of PFS 0.52 (95% CI, 0.27-0.99; P = .048) for the subgroup with PD-L1 TPS > 50%. Conclusions: For patients with NSCLC with PD-L1 TPS > 50%, pembrolizumab plus chemotherapy has a better PFS than pembrolizumab monotherapy in this meta-analysis. To confirm this finding, a prospective phase III trial that directly compares the treatments is warranted. (C) 2019 Elsevier Inc. All rights reserved. | - |
dc.language | 영어 | - |
dc.publisher | Cancer Information Group | - |
dc.title | First-line Pembrolizumab Versus Pembrolizumab Plus Chemotherapy Versus Chemotherapy Alone in Non-small-cell Lung Cancer: A Systematic Review and Network Meta-analysis | - |
dc.type | Article | - |
dc.contributor.AlternativeAuthor | 김동완 | - |
dc.contributor.AlternativeAuthor | 허대석 | - |
dc.identifier.doi | 10.1016/j.cllc.2019.05.009 | - |
dc.citation.journaltitle | Clinical Lung Cancer | - |
dc.identifier.wosid | 000481650500010 | - |
dc.identifier.scopusid | 2-s2.0-85066300766 | - |
dc.citation.endpage | 338.e4 | - |
dc.citation.number | 5 | - |
dc.citation.startpage | 331 | - |
dc.citation.volume | 20 | - |
dc.identifier.sci | 000481650500010 | - |
dc.description.isOpenAccess | N | - |
dc.contributor.affiliatedAuthor | Hahn, Seokyung | - |
dc.contributor.affiliatedAuthor | Kim, Dong-Wan | - |
dc.contributor.affiliatedAuthor | Heo, Dae Seog | - |
dc.type.docType | Review | - |
dc.description.journalClass | 1 | - |
dc.subject.keywordPlus | ADVANCED NSCLC | - |
dc.subject.keywordPlus | CISPLATIN | - |
dc.subject.keywordAuthor | Immunotherapy | - |
dc.subject.keywordAuthor | Meta-analysis | - |
dc.subject.keywordAuthor | Network meta-analysis | - |
dc.subject.keywordAuthor | Non-small cell lung cancer | - |
dc.subject.keywordAuthor | Pembrolizumab | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.